EYES Share Price | Vivani Medical, Inc. Stock Analysis & Recommendation

Q: What does Vivani Medical, Inc. do?

Overview: Vivani Medical, Inc. is engaged in developing, manufacturing, and marketing prosthetic devices that restore vision to blind individuals, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) Market cap: USD 68.13 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.00 Return on Equity: -204.31% Price to Book: 5.86Contact Details: Address: 12744 San Fernando Rd Bldg 3, SYLMAR CA: 91342-3853 Tel: 1 818 8335000 Fax: 1 818 8335067 Website: http://www.secondsight.com/

Q: Is Vivani Medical, Inc. overvalued or undervalued?

As of 13 August 2020, Vivani Medical, Inc. has moved from a valuation grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently overvalued, as evidenced by its Price to Book Value of 5.86, an EV to EBIT of -2.26, and an EV to EBITDA of -2.30, all of which reflect poor operational performance and financial instability.In comparison to its peers, Vivani Medical's valuation metrics are unfavorable. For instance, Cardiff Oncology, Inc. has a P/E ratio of -5.0384 and an EV to EBITDA of -3.2378, while Pro-Dex, Inc. stands out with a very attractive P/E of 15.6736 and an EV to EBITDA of 11.4415. Additionally, Vivani Medical's return performance has lagged significantly behind the S&P 500 over the past three and five years, with declines of 81.5% and 60.75%, respectively, further reinforcing the notion that the company is overvalued in its current state.

Q: Is Vivani Medical, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Vivani Medical, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different indicators. The MACD shows a mildly bearish trend on the weekly chart, while it is mildly bullish on the monthly chart. The Bollinger Bands indicate a bullish stance on both weekly and monthly time frames. Daily moving averages are bullish, but the KST and OBV are mildly bearish on the weekly and show no trend on the monthly. In terms of performance, the stock has outperformed the S&P 500 over the past week (22.50% vs. 1.05%) and month (18.55% vs. 2.33%), but it has significantly underperformed over the longer terms, particularly in the 3-year and 5-year periods.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

343.05 k

Shareholding (Sep 2025)

FII

1.77%

Held by 6 FIIs

DII

95.59%

Held by 3 DIIs

Promoter

0.00%

How big is Vivani Medical, Inc.?

22-Jun-2025

As of Jun 18, Vivani Medical, Inc. has a market capitalization of 68.13 million and reported net sales of 0.00 million with a net profit of -23.75 million over the last four quarters. The balance sheet shows shareholder's funds of 17.61 million and total assets of 41.56 million.

View full answer

What does Vivani Medical, Inc. do?

22-Jun-2025

Vivani Medical, Inc. develops and markets prosthetic devices aimed at restoring vision for blind individuals, operating in the Pharmaceuticals & Biotechnology sector with a market cap of $68.13 million. The company reported a net profit loss of $6 million as of March 2025.

View full answer

Who are in the management team of Vivani Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Vivani Medical, Inc. includes Chairman Gregg Williams, Acting CEO and Director Matthew Pfeffer, Director Jonathan McGuire, and Independent Director Aaron Mendelsohn. They are responsible for the company's strategic direction and operations.

View full answer

Is Vivani Medical, Inc. overvalued or undervalued?

25-Jun-2025

Vivani Medical, Inc. is currently overvalued and has moved from a risky to a "does not qualify" valuation grade due to poor financial health, reflected in unfavorable metrics compared to peers and significant declines in return performance relative to the S&P 500.

View full answer

Is Vivani Medical, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Vivani Medical, Inc. shows a neutral trend with mixed signals, being mildly bearish on the weekly MACD but bullish on the monthly, while outperforming the S&P 500 in the short term but underperforming over the longer three- and five-year periods.

View full answer

Compare Vivani Medical, Inc. with Similar Stocks

enVVeno Medical Corp.Avinger, Inc.Kewaunee Scientific Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 110 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.95

Return on Equity

-1,988.24%

Price to Book

84.15

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.27%

6 Months

-12.14%

1 Year

5.13%

2 Years

19.42%

3 Years

-16.33%

4 Years

-69.85%

5 Years

-81.61%

Vivani Medical, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-50.41%

EBIT Growth (5y)

-1.05%

EBIT to Interest (avg)

-21.53

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

7.71%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.86

EV to EBIT

-2.26

EV to EBITDA

-2.30

EV to Capital Employed

56.53

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-2500.70%

ROE (Latest)

-204.31%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (2.64%)

Foreign Institutions

Held by 6 Foreign Institutions (1.77%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -8.33% vs 11.76% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.60",
          "val2": "-6.20",
          "chgp": "-6.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.50",
          "val2": "-6.00",
          "chgp": "-8.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.56% vs -84.89% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.30",
          "val2": "-26.60",
          "chgp": "8.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.50",
          "val2": "-25.70",
          "chgp": "8.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.60

-6.20

-6.45%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-6.50

-6.00

-8.33%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -8.33% vs 11.76% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-24.30

-26.60

8.65%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-23.50

-25.70

8.56%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 8.56% vs -84.89% in Dec 2023

All Annual Results

Company CV

About Vivani Medical, Inc.

Vivani Medical, Inc.

Pharmaceuticals & Biotechnology

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

Company Coordinates

Company Details

12744 San Fernando Rd Bldg 3 , SYLMAR CA : 91342-3853

Tel: 1 818 8335000

http://www.secondsight.com/

Registrar Details

Vivani Medical, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Vivani Medical, Inc.?

Watch in Real-Time

What does Vivani Medical, Inc. do?

Who are in the management team of Vivani Medical, Inc.?

Is Vivani Medical, Inc. overvalued or undervalued?

Is Vivani Medical, Inc. technically bullish or bearish?

Compare Vivani Medical, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Vivani Medical, Inc.

Company Coordinates